NCT02601937 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02601937
Title	A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Epizyme, Inc.
Indications	kidney rhabdoid cancer rhabdoid cancer myoepithelial carcinoma extraskeletal myxoid chondrosarcoma collecting duct carcinoma atypical teratoid rhabdoid tumor epithelioid sarcoma epithelioid malignant peripheral nerve sheath tumor synovial sarcoma
Therapies	Tazemetostat
Age Groups:	child \| adult
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| DNK \| DEU \| CAN \| AUS

Additional content available in CKB BOOST